Speaker Profile

M.D., Chief Medical Officer, Delfi Diagnostics

Health policy and payment expert, pulmonary physician, and lung cancer epidemiologist, Peter has devoted his career to repairing defects in the healthcare delivery system that impede access to high-quality cancer care and working to ameliorate healthcare’s cost crisis. His work spans seminal studies including that identification of racial gaps in lung cancer care, the development of the first lung cancer risk prediction model (the “Bach model”), lead authorship on multiple lung screening guidelines, and definitional work on pharmaceutical pricing and value. Peter previously served as Senior Adviser at the US Centers for Medicare Medicaid Services and mentor on many National Institutes of Health K awards. He has been elected to the National Academy of Medicine, American Society for Clinical Investigation, and the Johns Hopkins Society of Scholars.

 Session Abstract – PMWC 2022 Silicon Valley

Track 5, June 29

Early cancer detection technologies have huge potentials to change disease outcome and patient management, yet most of these technologies are still in development. This session discusses latest technological and clinical advancements, clinical limitations and challenges to overcome, and the potential for future applications using the various types of early detection biomarkers.